Subscribe to RSS
Download PDF
DOI: 10.1055/s-0044-1792005
High-Grade Gastrointestinal Neuroendocrine Carcinomas: Multidisciplinary Approach Can Improve Survival Outcomes
Authors
Abstract
Purpose
There is limited evidence for the presentation patterns and outcomes of patients with high-grade gastrointestinal neuroendocrine carcinomas (HG-NEC).
Methods
Patients diagnosed with HG-NEC, defined as having a pathological diagnosis of neuroendocrine cancer with an epicenter of cancer in the gastrointestinal tract and Molecular Immunology Borstel-1 index ≥ 20% between May 2014 and May 2022 were retrospectively analyzed for demographic variables, survivals, and prognostic parameters. The primary endpoint of the study was the estimation of median overall survival (OS) by the Kaplan–Meier method.
Results
A total of 336 patients were included in the analysis, of whom 283 patients (84%) were started on cancer-directed treatment while 53 patients (16%) were planned for best supportive care. The most common sites of the primary were gallbladder (45%), colorectal (19%), and pancreas (13%), with 253 patients (75%) having metastatic NEC. All treated patients received systemic therapy (commonly platinum and etoposide), while 64 patients (23%) underwent resection of the primary. With a median follow-up of 65.4 (45.6 -85.3) months, the median OS of the entire cohort was 15.8 months. The prospective multidisciplinary tumor (MDT) board decision of classifying patients into resectable, unresectable, and metastatic HG-NEC was prognostic for OS (26.8 vs. 21.1 vs. 13.5 months; p = 0.001). Patients who were able to undergo multimodality therapy (resection and systemic therapy) had improved OS compared with patients on systemic therapy alone (23.1 vs. 14.9 months; p = 0.003).
Conclusion
A majority of patients with HG-NEC present with advanced disease. An MDT is essential to deciding initial therapeutic strategies in these patients, with patients undergoing resection and systemic therapy having improved OS.
Keywords
gallbladder NEC - high-grade gastrointestinal neuroendocrine carcinoma - MDT - multidisciplinary tumor board - NECPublication History
Received: 02 August 2024
Accepted: 21 September 2024
Article published online:
07 November 2024
© 2024. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Sorbye H, Welin S, Langer SW. et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 2013; 24 (01) 152-160
- 2 Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival according to primary tumor location, stage, and treatment patterns in locoregional gastroenteropancreatic high-grade neuroendocrine carcinomas. Oncologist 2022; 27 (04) 299-306
- 3 Dingemans AC, Früh M, Ardizzoni A. et al; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆ . Ann Oncol 2021; 32 (07) 839-853
- 4 Mitry E, Baudin E, Ducreux M. et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81 (08) 1351-1355
- 5 Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; Jul 15; 68 (02) 227-232
- 6 India Population. 2024 (Live). Accessed October 12, 2024 at: https://worldpopulationreview.com/countries/india-population
- 7 Nandy K, Patkar S, Yadav S. et al. Neuroendocrine neoplasms of the gallbladder: a single institute analysis of outcomes and prognostic factors. J Surg Oncol 2024; 129 (06) 1121-1130
- 8 Noda K, Nishiwaki Y, Kawahara M. et al; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002; 346 (02) 85-91
- 9 NABNEC. A randomised phase II study of nab-paclitaxel in combination with carboplatin as first line treatment of gastrointestinal neuroendocrine carcinomas (GI-NECs). | Journal of Clinical Oncology [Internet]. Accessed August 6, 2024 at: https://ascopubs.org/doi/10.1200/JCO.2024.42.3_suppl.589
- 10 Paz-Ares L, Dvorkin M, Chen Y. et al; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet 2019; 394 (10212): 1929-1939
- 11 Capdevila J, Hernando J, Teule A. et al. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin. Nat Commun 2023; 14 (01) 2973
- 12 van Riet J, van de Werken HJG, Cuppen E. et al. The genomic landscape of 85 advanced neuroendocrine neoplasms reveals subtype-heterogeneity and potential therapeutic targets. Nat Commun 2021; 12 (01) 4612